Trial Profile
Phase I study of Iressa [gefitinib] and CRT [chemo radio-therapy]/IMRT [intensity modulated radiation therapy] in Chinese patients with IIIB/IV NSCLC [non-small cell lung cancer] after failure of platinum-based chemotherapy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Aug 2007 New trial record.